GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2007

Asuragen Accesses Xenomic’s NPM1 Technology for Diagnostic Development

  • Xenomics granted Asuragen coexclusive, worldwide rights to incorporate NPM1 technology into Asuragen's molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture, and market products for the diagnosis, stratification, and monitoring of patients with acute myeloid leukemia (AML).

    A recent discovery, for which Xenomics holds exclusive rights, showed that many AML patients have mutations in the nucleophosmin (NPM1) gene, a favorable marker for clinical outcome. It is hoped that the results of such a test will help physicians select patients with a good prognosis of benefiting from intensive chemotherapy.

    The NPM1 mutation may also be used to monitor AML patients for residual disease during chemotherapy.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?